改良剂量密集型紫杉醇联合铂类新辅助化疗用于晚期卵巢癌患者的效果

Effects of modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy in treatment of patients with advanced ovarian cancer

目的:观察改良剂量密集型紫杉醇联合铂类新辅助化疗用于晚期卵巢癌患者的效果。方法:选取2020年3月至2022年3月该院收治的112例晚期卵巢癌患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各56例。对照组给予传统新辅助化疗方案紫杉醇联合铂类治疗,观察组给予改良剂量密集型紫杉醇联合铂类新辅助化疗,比较两组疾病控制率、血清肿瘤标志物[糖类抗原125(CA125)、癌胚抗原(CEA)、特异性组织多肽抗原(TPS)]水平、不良反应发生率、转移率及6个月生存率。结果:观察组疾病控制率为80.36%(45/56),高于对照组的62.50%(35/56),差异有统计学意义(P<0.05);治疗后,两组CA125、TPS、CEA水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组贫血、中性粒细胞/白细胞减少及其他不良反应发生率比较,差异均无统计学意义(P>0.05);观察组胃肠道不良反应发生率为25.00%(14/56),低于对照组的44.64%(25/56),差异有统计学意义(P<0.05);观察组转移率低于对照组,6个月生存率高于对照组,差异有统计学意义(P<0.05)。结论:改良剂量密集型紫杉醇联合铂类新辅助化疗用于晚期卵巢癌患者可提高疾病控制率和6个月生存率,以及降低血清肿瘤标志物指标水平、胃肠道不良反应发生率、肿瘤转移率,效果优于传统新辅助化疗方案紫杉醇联合铂类治疗。

Objective:To observe effects of modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy in treatment of patients with advanced ovarian cancer.Methods:A prospective study was conducted on 112 patients with advanced ovarian cancer admitted to this hospital from March 2020 to March 2022.According to the random number table method,they were divided into control group and observation group,56 cases in each group.The control group was treated with traditional neoadjuvant chemotherapy regimen of Paclitaxel combined with Platinum,while the observation group was treated with modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy.The disease control rate,the serum tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),specific tissue polypeptide antigen(TPS)]levels,the incidence of adverse reactions,the metastasis rate,and the 6-month survival rate were compared between the two groups.Results:The disease control rate of the observation group was 80.36%(45/56),which was higher than the control group of 62.50%(35/56),and the difference was statistically significant(P<0.05).After the treatment,the levels of CA125,TPS and CEA in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of anemia,neutropenia/leukopenia and other adverse reactions between the two groups(P>0.05).The incidence of gastrointestinal adverse reactions in the observation group was 25.00%(14/56),which was lower than 44.64%(25/56)in the control group,and the difference was statistically significant(P<0.05).The metastasis rate of the observation group were lower than those of the control group,the 6-month survival rate was higher than that of the control group,and the differences were statistically significant(P<0.05).Conclusions:The modified dose-dense Paclitaxel combined with Platinum neoadjuvant chemotherapy in the treatment of the patients with advanced ovarian cancer can improve the disease control rate and the 6-month survival rate,and reduce the levels of serum tumor markers,the incidence of gastrointestinal adverse reactions,the tumor metastasis rate.Moreover,it is superior to the traditional neoadjuvant chemotherapy regimen of Paclitaxel combined with Platinum.